Read by QxMD icon Read

Lung cancer,meta-analysis

Valliappan Muthu, Inderpaul Singh Sehgal, Sahajal Dhooria, Ashutosh N Aggarwal, Ritesh Agarwal
BACKGROUND AND AIM: The optimal modality for re-staging the mediastinum following neoadjuvant therapy for lung cancer remains unclear. Surgical methods are currently considered the reference standard. Herein, we evaluate the role of endosonographic techniques for mediastinal re-staging in lung cancer. METHODS: Systematic review of PubMed and EmBase databases was performed to identify studies utilizing endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) or a combination (CUS) for mediastinal re-staging following induction therapy for stage III lung cancer...
April 20, 2018: Chest
Hazem El-Osta, Pushan Jani, Ali Mansour, Philip Rascoe, Syed Jafri
RATIONALE: An accurate assessment of the mediastinal lymph nodes status is essential in the staging and treatment planning of potentially resectable non-small cell lung cancer (NSCLC). OBJECTIVES: We performed this meta-analysis to evaluate the role of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in detecting occult mediastinal disease in NSCLC with no radiologic mediastinal involvement. METHODS: The PubMed, Embase, and Cochrane libraries were searched for studies describing the role of EBUS-TBNA in lung cancer patients with radiologically negative mediastinum...
April 23, 2018: Annals of the American Thoracic Society
Joseph A Pinto, Carlos S Vallejos, Luis E Raez, Luis A Mas, Rossana Ruiz, Junior S Torres-Roman, Zaida Morante, Jhajaira M Araujo, Henry L Gómez, Alfredo Aguilar, Denisse Bretel, Claudio J Flores, Christian Rolfo
Background: There are well-known differences in gender outcome in non-small cell lung cancer (NSCLC) and other cancers. In this work, we evaluated several randomised clinical trials to explore the gender influence in the outcome of patients with NSCLC treated with targeted therapy and immunotherapy. Methods: We performed a series of meta-analysis to compare the gender outcome in the routine setting for overall survival and progression-free survival (PFS) in phase III randomised clinical trials comparing EGFR inhibitors versus chemotherapy (OPTIMAL, LUX-lung 3, LUX-lung 6, EURTAC, ENSURE and WTJOG); ALK inhibitors versus chemotherapy (ASCEND 4, ASCEND 5, PROFILE 1014 and NCT009323893) and anti-PD1 checkpoint inhibitors versus chemotherapy (CheckMate 017, CheckMate 026, CheckMate 057, KEYNOTE 010 and KEYNOTE 024)...
2018: ESMO Open
Wei You, Mei Liu, Ji-Dong Miao, Yu-Qian Liao, Yi-Bing Song, Dian-Kun Cai, Yang Gao, Hao Peng
Background : This network meta-analysis aimed at comparing anti-programmed death 1 (anti-PD-1) with anti-programmed death ligand 1(anti-PD-L1) immunotherapy in patients with metastatic, previously treated non-small cell lung cancer (NSCLC) who failed first-line treatment. Methods : We searched electronic databases to identify all eligible clinical trials. End-points included overall survival (OS), progression-free survival (PFS) and objective response. Hazard ratios (HRs) or odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were extracted...
2018: Journal of Cancer
Rong-Quan He, Wei-Luan Cen, Jie-Mei Cen, Wei-Ning Cen, Jia-Yi Li, Mei-Wei Li, Ting-Qing Gan, Xiao-Hua Hu, Gang Chen
BACKGROUND/AIMS: Since the function of microRNA (miR)-210 in non-small cell lung cancer (NSCLC) remains unclear, we aimed to explore the clinical significance of miR-210 in NSCLC. METHODS: NSCLC-related data from 1673 samples on Gene Expression Omnibus and 1090 samples on The Cancer Genome Atlas were obtained and analyzed. The expression level of miR-210 was validated via real-time quantitative PCR analysis with 125 paired clinical samples. A meta-analysis was performed to generate a comprehensive understanding of miR-210 expression and its clinical significance in NSCLC...
April 13, 2018: Cellular Physiology and Biochemistry
Wenxiong Zhang, Yiping Wei, Dongliang Yu, Jianjun Xu, Jinhua Peng
BACKGROUND: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis compared their effectiveness and safety. METHODS: We searched systematically in PubMed, ScienceDirect, The Cochrane Library, Scopus, Ovid MEDLINE, EMBASE, Web of Science, and Google Scholar for relevant clinical trials regarding gefitinib versus erlotinib for NSCLC. Antitumor effectiveness (overall survival [OS], progression-free survival [PFS], objective response rate [ORR] and disease control rate [DCR]) and adverse effects [AEs]) were assessed...
April 2018: Medicine (Baltimore)
Stefano Corbella, Paolo Veronesi, Viviana Galimberti, Roberto Weinstein, Massimo Del Fabbro, Luca Francetti
BACKGROUND: The aim of the present systematic review was to evaluate the hypothesis of an association between periodontitis and the development of cancer. METHODS: Two reviewers independently screened electronic and manual sources for pertinent articles. Primary outcome measures were the occurrence of neoplasm diagnosis in exposed and non-exposed groups, reported to evaluate association between cancer and periodontitis. RESULTS: Of the 490 initially retrieved papers 10 were included in the qualitative synthesis and eight in the quantitative synthesis; the eight papers covered six studies...
2018: PloS One
Zhenzhen Zhang, Raymond Bergan, Jackilen Shannon, Christopher G Slatore, Gerd Bobe, Yumie Takata
Lung cancer remains a leading cause of cancer-related deaths in the United States. Although smoking and air pollution exposure are primary risk factors of lung cancer, diet has also been reported to contribute to lung cancer risk. Cruciferous vegetables contain many bioactive compounds that alter the detoxification process of air-borne carcinogenic compounds and, thereby, may decrease lung cancer risk. In our meta-analysis of 31 observational studies, cruciferous vegetable intake was inversely associated with lung cancer risk (summary odds ratio/relative risk = 0...
April 16, 2018: Molecular Nutrition & Food Research
Sipeng Shen, Ruyang Zhang, Yichen Guo, Elizabeth Loehrer, Yongyue Wei, Ying Zhu, Qianyu Yuan, Sebastian Moran, Thomas Fleischer, Maria Moksnes Bjaanaes, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, Li Su, Feng Chen, David C Christiani
B-cell translocation gene 2 (BTG2) is a tumor suppressor protein and is known to be downregulated in several types of cancer. In this study, we investigated a potential role for BTG2 in early-stage non-small cell lung cancer (NSCLC) survival. We analysed BTG2 methylation data from 1,230 early-stage NSCLC patients from five international cohorts, as well as gene expression data from 3,038 lung cancer cases from multiple cohorts. Three CpG probes (cg01798157, cg06373167, cg23371584) that detected BTG2 hypermethylation in tumor tissues were associated with lower overall survival...
April 15, 2018: Molecular Oncology
Jue Wang, Guochun Li, Lili Yu, Tingting Mo, Qibiao Wu, Zhou Zhou
ETHNOPHARMACOLOGICAL RELEVANCE: Aidi injection is one of the most commonly used Chinese patent medicines for advanced non-small cell lung cancer (NSCLC). It is made from an extraction of Mylabris Phalerata, Radix Astragalus, Radix Ginseng, and Acanthopanax Senticosus. AIM OF THE STUDY: The objective of this study is to evaluate the efficacy and safety of Aidi injection in combination with platinum-based chemotherapy for stage IIIB/IV NSCLC. MATERIALS AND METHODS: A systematic review and meta-analysis were performed following the PRISMA (the Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines...
April 12, 2018: Journal of Ethnopharmacology
Dai Fuhong, Gao Xiang, Li Haiying, Wang Jiangye, Gao Xueming, Chai Wenxiao
BACKGROUND: Brucea javanica oil emulsion (BJOE) is traditional Chinese medicine with implicated anti-tumor activity, which has been used for treating lung cancer in China. The aim of this investigation was to evaluate the effects and safety of intrapleural injection of BJOE in treating malignant pleural effusion (MPE). METHODS: The randomised controlled trials (RCTs) on the effects and safety of BJOE in treating MPE were searched from electronic medical database including MEDLINE, SCI, EMBASE, Cochrance Library and CNKI...
April 12, 2018: BMC Cancer
Hanbo Chen, Joanna M Laba, R Gabriel Boldt, Christopher D Goodman, David A Palma, Suresh Senan, Alexander V Louie
PURPOSE: As no completed randomized trials of surgery versus stereotactic ablative radiation therapy (SABR) in patients with early-stage non-small cell lung cancer are available, numerous propensity score studies have attempted to mimic the setting of clinical trials using nonrandomized data. We performed a meta-analysis of propensity score studies comparing SABR and surgery. METHODS AND MATERIALS: The MEDLINE and Embase databases were queried up to December 2016...
May 1, 2018: International Journal of Radiation Oncology, Biology, Physics
Xiao-Ning Gan, Ting-Qing Gan, Rong-Quan He, Jie Luo, Rui-Xue Tang, Han-Lin Wang, Hong Zhou, Hui Qing, Jie Ma, Xiao-Hua Hu, Gang Chen
The role of microRNA (miRNA)-452-5p in lung squamous cell carcinoma (LUSC) remains unclear. Therefore, the present systematic study was performed to investigate the clinical significance and the rudimentary mechanism of the function of miR-452-5p in LUSC. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were utilized to confirm the expression level and clinical value of miR-452-5p in LUSC. Using online databases and bioinformatic software, gene ontology (GO), pathway and protein-protein interaction (PPI) analyses of miR-452-5p target genes were performed to examine the molecular mechanism of miR-452-5p...
May 2018: Oncology Letters
Guangzhi Ma, Yunfu Deng, Hai Jiang, Wen Li, Qiang Wu, Qinghua Zhou
BACKGROUND: Programmed cell death-ligand 1 (PD-L1) seemed to be associated with the outcomes of non-small cell lung cancer. However the prognostic role of PD-L1 expression among NSCLC remained unclear and inconsistent. The aim of the study set out to evaluate the correlation between PD-L1 expression and the prognosis of patients that developed NSCLC. METHODS: Identified literatures were extracted of various electronic databases and a meta-analysis was performed to evaluate the prognostic role of PD-L1 among NSCLC patients...
March 31, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
Zheng Xiao, Chengqiong Wang, Rui Zhou, Shanshan Hu, Nian Yi, Jihong Feng, Minghua Zhou, Shiyu Liu, Ling Chen, Jie Ding, Qihai Gong, Fushan Tang, Xiaofei Li
OBJECTIVES: Aidi injection can significantly improve clinical response and reduce radiochemotherapy related toxicity. Can Aidi injection improve the survival in non-small-cell lung cancer (NSCLC)? Therefore, to further reveal it, we systematically evaluated all related studies. METHODS: We collected all studies about Aidi injection for NSCLC in Medline, Embase, Web of Science(ISI), China National Knowledge Infrastructure Database(CNKI), Chinese Scientific Journals Full-Text Database(VIP), Wanfang, China Biological Medicine Database (CBM), Cochrane Central Register of Controlled Trials (CENTRAL), Chinese clinical trial registry (Chi-CTR) and WHO International Clinical Trials Registry Platform (WHO-ICTRP), and US-clinical trials (established to June 2016)...
April 2018: Complementary Therapies in Medicine
Eman A Toraih, Alia Ellawindy, Salma Y Fala, Essam Al Ageeli, Nawal S Gouda, Manal S Fawzy, Somaya Hosny
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide. The oncogenic function of the long non-coding RNA; metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in HCC remains unclear. We aimed to evaluate MALAT1 serum expression profile in HCC and explore its relation to the clinicopathological features. Quantitative Real Time-Polymerase Chain Reaction was applied in 70 cohorts (30 HCC, 20 HCV, 20 controls). Further meta-analysis of clinical studies and in vitro validated experiments was employed...
March 28, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Jon Zabaleta, Tomohiko Iida, Pierre E Falcoz, Samer Salah, José R Jarabo, Arlene M Correa, Maria G Zampino, Takashi Matsui, Sukki Cho, Francesco Ardissone, Kazuhiro Watanabe, Michel Gonzalez, Pascal Gervaz, Jose I Emparanza, Víctor Abraira
OBJECTIVES: To assess the impact of a history of liver metastases on survival in patients undergoing surgery for lung metastases from colorectal carcinoma. METHODS: We reviewed recent studies identified by searching MEDLINE and EMBASE using the Ovid interface, with the following search terms: lung metastasectomy, pulmonary metastasectomy, lung metastases and lung metastasis, supplemented by manual searching. Inclusion criteria were that the research concerned patients with lung metastases from colorectal cancer undergoing surgery with curative intent, and had been published between 2007 and 2014...
March 21, 2018: European Journal of Surgical Oncology
Jun Shi, Weidong Leng, Lunhua Zhao, Cai Deng, Chenli Xu, Jue Wang, Yu Wang, Xingchun Peng
Conflicting results to identify the relationship between tooth loss and cancer risk. Therefore, a dose-response meta-analysis was performed to clarify and quantitative assessed the correlation between tooth loss and cancer risk. Up to March 2017, 25 observational epidemiological studies were included in current meta-analysis. Tooth loss was significantly associated with a higher risk of cancer. Additionally, tooth loss was associated with significantly a higher risk of esophageal cancer, gastric cancer, head and neck cancer, colorectal cancer, pancreas cancer, lung cancer, prostate cancer, bladder cancer and hematopoietic cancer...
March 13, 2018: Oncotarget
Bingbing Qiao, Wenqin Luo, Yanna Liu, Jing Wang, Chuan Liu, Zhao Liu, Sizhe Chen, Jingjing Gu, Xiaolong Qi, Tongwei Wu
Background & Aims: Quite a few studies had investigated the correlation between CXC chemokine receptor 2 (CXCR2) and cancer. This meta-analysis was aimed to comprehensively summarize the previous studies and to explore the prognostic value of CXCR2 in patients with cancer. Materials and Methods: An adequate literature search in EMBASE and PubMed was conducted. Articles in English which have reported CXCR2 expression in patients and enough data to calculate hazard ratio (HR) were included...
March 13, 2018: Oncotarget
Baoqi Duan, Jinsong Xie, Qinglin Rui, Wenxi Zhang, Zhaoqing Xi
PURPOSE: Shengmai injection (SMI) has shown promising outcomes in the management of non-small cell lung cancer (NSCLC). This meta-analysis aimed to investigate the add-on effects of SMI to chemotherapy in NSCLC patients. METHODS: A comprehensive literature search was performed in the Cochrane Library, PubMed, Embase, CNKI, VIP, and Wanfang up to December 2017. Only randomized controlled trials (RCTs) evaluating SMI in combination with chemotherapy versus chemotherapy alone in NSCLC patients were eligible...
March 29, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"